Location History:
- Ume.ang., SE (1998)
- Ume{dot over (a)}, SE (2001)
Company Filing History:
Years Active: 1998-2001
Title: The Innovative Contributions of Bernt Eric Uhlin
Introduction
Bernt Eric Uhlin, an accomplished inventor based in Umeå, Sweden, has made significant strides in the field of immunology through his innovative patents. With a total of two registered patents under his name, Uhlin's work primarily focuses on developing antibodies and vaccines targeting pathogenic bacteria that pose risks to mammalian health.
Latest Patents
Uhlin's most recent patents include:
1. **Anti-bodies binding adhesin-derived antigens** - This patent concerns an antigen that serves as a major immunizing component comprising a determinant of an adhesin polypeptide. It outlines antibodies that react with this determinant, targeting pathogenic bacteria that adhere to mammalian tissues.
2. **Vaccines against disease caused by pathogenic pilus-forming bacteria** - This patent similarly focuses on an antigen with key immunizing components against bacteria responsible for significant diseases in mammals. The invention highlights both antibodies and DNA that express the antigen, facilitating robust immune responses.
Career Highlights
Currently, Uhlin is part of Symbicom Aktiebolag, where he continues to advance his research and contribute to the field of biotechnology. His background includes extensive research and development experience, particularly in the realms of immunology and pathogen resistance.
Collaborations
Throughout his career, Uhlin has collaborated with respected colleagues, including Frederik Carl Lindberg and Jan Staffan Normark. These partnerships have fostered an environment of shared knowledge, leading to breakthroughs that enhance understanding and treatment of bacterial infections.
Conclusion
Bernt Eric Uhlin's contributions to science through his innovative patents are crucial in the ongoing battle against pathogenic bacteria. His work at Symbicom Aktiebolag and collaborations with distinguished peers reflect a commitment to improving public health through advanced immunological research. As our understanding of these pathogens evolves, the significance of Uhlin's innovations will undoubtedly continue to grow.